Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 6/20 | 1.00 |
| ▸ | G6PD | P11413 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 4/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | GABRP | O00591 | 2/20 | 0.70 |
| ▸ | GABRD | O14764 | 2/20 | 0.70 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.70 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.70 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.70 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.70 |
| ▸ | GABRE | P78334 | 2/20 | 0.70 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfaxalone SCHEMBL57756 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Renanolone SCHEMBL5610376 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL9436587 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614070 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24766358 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614107 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24675016 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614053 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL24765814 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 | |
| Alfaxalone SCHEMBL21614074 | 1.00 | GABRA1 (1.00) | GABRA1GABRB2G6PDCYP3A4GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183238-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2023-06-15 | — | — | US | claimed |
| EP-4153549-A2 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Certego Therapeutics Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | Certego Therapeutics Inc. (US) | 2023-03-07 | — | — | US | claimed |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | CERTEGO ABC, LLC | 2022-04-28 | — | — | US | claimed |
| US-20220008398-A1 | GABOXADOL FOR REDUCING RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION | Certego Therapeutics (US) | 2022-01-13 | — | — | US | claimed |
| WO-2021236876-A2 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | Certego Therapeutics Inc. (US) | 2021-11-25 | — | — | WO | claimed |
| EP-3883566-A1 | GABOXADOL FOR REDUCING RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION | Certego Therapeutics Inc. (US) | 2021-09-29 | — | — | EP | claimed |
| US-11123332-B2 | Gaboxadol for reducing risk of suicide and rapid relief of depression | Certego Therapeutics Inc. (US) | 2021-09-21 | — | — | US | claimed |
| US-10966965-B2 | — | — | 2021-04-06 | — | — | US | claimed |
| US-20200155522-A1 | GABOXADOL FOR REDUCING RISK OF SUICIDE AND RAPID RELIEF OF DEPRESSION | Certego Therapeutics (US) | 2020-05-21 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | Belhaven BioPharma Inc. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2026076495-A1 | METHOD OF TREATMENT OR INHIBITION | TRKB Investments Pty Ltd (AU) | 2026-04-16 | — | — | WO | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183238-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | GABRA1 8/4885GABRB2 14/4885G6PD 2073/4885 |
| US-12616807-B2 | Medical counter measures including dry powder formulations and associated methods | ADRB2, ADRB3, MC5R | GABRA1 1034/4885GABRB2 1081/4885G6PD 3208/4885 |
| US-20220127261-A1 | RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | GABRD, GABRA6, GABRA3 | GABRA1 8/4885GABRB2 14/4885G6PD 2073/4885 |
| US-11597726-B2 | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders | GABRD, GABRA6, GABRA3 | GABRA1 8/4885GABRB2 14/4885G6PD 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.